telehealth glp-1 prescription texas Tirzepatide In Texas' Best Virtual Weight Loss

Scientific References Novel GLP-1-based Medications for Type 2 Diabetes and Obesity

Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]

Unlike some clinics that allow members to pay out of pocket for compounded medications, Calibrate sticks strictly to FDA-approved options routed through insurance

E., Telem, D

Other Diabetes Medications: Metformin, SGLT2 inhibitors, and DPP-4 inhibitors may be suitable alternatives

Tirzepatide doses of 10 mg and 15 mg resulted in lower body weight reductions of 12.8% and 14.7% respectively in individuals with overweight or obesity and T2DM [121]